title: Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine.
abstract: The potential antiarrhythmic efficacy of pharmacologic parasympathetic activation is still controversial. This study assessed the antiarrhythmic effect of saline solution (n = 9) and of the muscarinic agonist oxotremorine (1.5 micrograms/kg administered intravenously) (n = 17) in a feline animal model in which malignant arrhythmias were reproducibly elicited by the combination of acute myocardial ischemia and left stellate ganglion stimulation. Although saline solution had no effect, oxotremorine significantly decreased heart rate, blood pressure, the incidence of ventricular fibrillation from 47% to 0% (p = 0.004), and the incidence of malignant arrhythmias (either ventricular tachycardia or ventricular fibrillation) from 88% to 12% (p less than 0.001). When reduction in heart rate was prevented by means of atrial pacing (n = 15), the incidence of malignant arrhythmias was still significantly reduced from 87% to 27% (p = 0.001). Arrhythmias were also graded as follows: 0 = no premature ventricular contractions; 1 = 1 to 10 premature ventricular contractions; 2 = 11 to 50 premature ventricular contractions; 3 = ventricular tachycardia; 4 = ventricular fibrillation. Arrhythmia severity was 3.29 +/- 0.16 (SEM) in the control trials and was reduced to 0.76 +/- 0.26 (p less than 0.001) by oxotremorine and to 1.53 +/- 0.34 by oxotremorine and pacing (p = 0.002). Therefore a muscarinic agonist can significantly reduce malignant arrhythmias during acute myocardial ischemia and may represent a novel approach to the prevention of sudden cardiac death.
authors.affiliation: Centro di Fisiologia Clinica e Ipertensione, University of Milan, Italy.
authors.forename: G M
authors.initials: GM
authors.lastname: De Ferrari
authors.forename: E
authors.initials: E
authors.lastname: Vanoli
authors.forename: P
authors.initials: P
authors.lastname: Curcuruto
authors.forename: G
authors.initials: G
authors.lastname: Tommasini
authors.forename: P J
authors.initials: PJ
authors.lastname: Schwartz
mesh_terms: D000818:Animals; D005117:Cardiac Complexes, Premature / Q000209:etiology / Q000517:prevention & control*; D002304:Cardiac Pacing, Artificial; D002415:Cats; D003327:Coronary Disease / Q000150:complications; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D004562:Electrocardiography; D006439:Hemodynamics / Q000187:drug effects*; D010095:Oxotremorine / Q000494:pharmacology* / Q000627:therapeutic use; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000502:physiology; D012965:Sodium Chloride / Q000494:pharmacology; D013233:Stellate Ganglion / Q000502:physiology; D013610:Tachycardia / Q000209:etiology / Q000517:prevention & control*; D014693:Ventricular Fibrillation / Q000209:etiology / Q000517:prevention & control*
chemical_list: D011976:Receptors, Muscarinic; D012965:Sodium Chloride; D010095:Oxotremorine